With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships

The recent downturn in the biotechnology sector affected startups in many ways, from the availability of financing to the types of research they pursued. A report J.P. Morgan analysts published late last month suggests yet another ripple effect: a seeming shift in the terms young drugmakers receive in partnership deals.